Live attenuated vaccine: the first clinically approved dengue vaccine?

References

• Sabchareon A, Wallace D, Lang J, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012;380(9853):1559-67
   PubMed Web of Science ®Google Scholar
• Xu M, Hadinoto V, Appanna R, et al. Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes. J Immunol 2012;189(12):5877-85
   PubMedGoogle Scholar
• Anderson KB, Gibbons RV, Cummings DA, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 2013; Epub ahead of print
   Google Scholar
• Endy TP, Anderson KB, Nisalak A, et al. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis 2011;5(3):e975
   PubMed Web of Science ®Google Scholar
• Olkowski S, Forshey BM, Morrison AC, et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 2013;208(6):1026-33
   PubMed Web of Science ®Google Scholar
• Zellweger RM, Miller R, Eddy WE, et al. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 2013;9(10):e1003723
   PubMed Web of Science ®Google Scholar
• Rivino L, Kumaran EA, Jovanovic V, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 2013;87(5):2693-706
   PubMed Web of Science ®Google Scholar
• Yauch LE, Prestwood TR, May MM, et al. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 2010;185(9):5405-16
   PubMed Web of Science ®Google Scholar
• Yauch LE, Zellweger RM, Kotturi MF, et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009;182(8):4865-73
   PubMed Web of Science ®Google Scholar
• Durbin AP, Kirkpatricka BD, Pierce KK, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double blind clinical trial. J Infect Dis 2013;207(6):957-65
   PubMed Web of Science ®Google Scholar
• Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011;29(42):7251-60
   PubMed Web of Science ®Google Scholar
• Li XF, Deng Y-Q, Yang H-Q, et al. A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J Virol 2013;87(24):13694-705
   PubMedGoogle Scholar
• Züst R, Dong H, Li XF, et al. Rational design of a live attenuated dengue vaccine: 2′-O-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog 2013;9(8):e1003521
   PubMed Web of Science ®Google Scholar
• Durbin AP, Schmidt A, Elwood D, et al. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. J Infect Dis 2011;203(3):327-34
   PubMedGoogle Scholar
• Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011;24(5):442-50
   PubMed Web of Science ®Google Scholar
• Huang CY, Kinney RM, Livengood JA, et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis 2013;7(5):e2243
   PubMed Web of Science ®Google Scholar
• Lai CY, Tsai WY, Lin SR, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008;82(13):6631-43
   PubMed Web of Science ®Google Scholar
• Hughes HR, Crill WD, Chang GJ. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J 2012;9:115
   PubMed Web of Science ®Google Scholar
• Christian EA, Kahle KM, Mattia K, et al. Atomic-level functional model of dengue virus Envelope protein infectivity. Proc Natl Acad Sci USA 2013;110(46):18662-7
   PubMedGoogle Scholar
• Halstead SB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013;31(41):4501-7
   PubMed Web of Science ®Google Scholar